Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. The company has developed nebokitug, a monoclonal antibody designed to bind and block the activity of the soluble protein CCL24. Nebokitug targets CCL24, also known as eotaxin-2, a chemokine that promotes cellular processes regulating inflammatory and fibrotic activities through the CCR3 receptor. CCL24 is expressed in immune cells, endothelial cells, and epithelial cells. Nebokitug is a novel CCL24 inhibiting product candidate with dual anti-fibrotic and anti-inflammatory activity. This approach is being developed for difficult-to-treat rare diseases, or orphan indications, such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), for which patients lack established disease-modifying or standard-of-care treatment options. The company estimates approximately 70,000 patients suffer from PSC in the United States, European Union, and Japan, representing a more than $1 billion market opportunity. Approximately 170,000 patients suffer from SSc in these same markets, representing a more than $1.5 billion market opportunity. Nebokitug, the lead clinical product candidate, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways. The company has completed a Phase 2 clinical study in PSC, a rare obstructive and cholestatic liver disease. Positive topline results from the double-blinded portion of this trial were reported in July 2024, and results from the open label part were reported in March 2025. The company had an End-of-Phase 2 meeting with the FDA in December 2024.